IBRANCE Drug Patent Profile

When do Ibrance patents expire, and when can generic versions of Ibrance launch?

Ibrance is a drug marketed by Pfizer and is included in two NDAs. There are three patents protecting this drug and two Paragraph IV challenges.

This drug has one hundred and sixty-nine patent family members in fifty-six countries.

The generic ingredient in IBRANCE is palbociclib. There are thirteen drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the palbociclib profile page.

DrugPatentWatch^® Generic Entry Outlook for Ibrance

Ibrance was eligible for patent challenges on February 3, 2019.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be August 8, 2034. This may change due to patent challenges or generic licensing.

There have been thirty-eight patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

There are nine tentative approvals for the generic drug (palbociclib), which indicates the potential for near-term generic launch.

Indicators of Generic Entry

Summary for IBRANCE

International Patents:	169
US Patents:	3
Applicants:	1
NDAs:	2
Finished Product Suppliers / Packagers:	2
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	128
Patent Applications:	5,469
Drug Prices:	Drug price information for IBRANCE
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for IBRANCE
What excipients (inactive ingredients) are in IBRANCE?	IBRANCE excipients list
DailyMed Link:	IBRANCE at DailyMed

See drug prices for IBRANCE

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for IBRANCE

Constraining patent/regulatory exclusivity:

10,723,730*PED

NDA:

207103

Dosage:

CAPSULE;ORAL

Constraining patent/regulatory exclusivity:

11,065,250*PED

NDA:

212436

Dosage:

TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for IBRANCE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
University Medical Center Groningen	Phase 4
Megalabs	PHASE4
AstraZeneca	Phase 1/Phase 2

See all IBRANCE clinical trials

Pharmacology for IBRANCE

Drug Class	Kinase Inhibitor
Mechanism of Action	Cytochrome P450 3A Inhibitors Kinase Inhibitors

Paragraph IV (Patent) Challenges for IBRANCE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
IBRANCE	Tablets	palbociclib	75 mg, 100 mg and 125 mg	212436	1	2020-11-24
IBRANCE	Capsules	palbociclib	75 mg, 100 mg and 125 mg	207103	12	2019-02-04

US Patents and Regulatory Information for IBRANCE

IBRANCE is protected by three US patents and two FDA Regulatory Exclusivities.

This potential generic entry date is based on patent 10,723,730.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Pfizer	IBRANCE	palbociclib	CAPSULE;ORAL	207103-001	Feb 3, 2015		RX	Yes	No	RE47739*PED				Y
Pfizer	IBRANCE	palbociclib	TABLET;ORAL	212436-002	Nov 1, 2019		RX	Yes	No	RE47739*PED				Y
Pfizer	IBRANCE	palbociclib	TABLET;ORAL	212436-003	Nov 1, 2019		RX	Yes	Yes	10,723,730*PED				Y
Pfizer	IBRANCE	palbociclib	CAPSULE;ORAL	207103-002	Feb 3, 2015		RX	Yes	No
Pfizer	IBRANCE	palbociclib	CAPSULE;ORAL	207103-001	Feb 3, 2015		RX	Yes	No

Expired US Patents for IBRANCE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Pfizer	IBRANCE	palbociclib	CAPSULE;ORAL	207103-002	Feb 3, 2015	7,208,489
Pfizer	IBRANCE	palbociclib	CAPSULE;ORAL	207103-002	Feb 3, 2015	7,456,168
Pfizer	IBRANCE	palbociclib	TABLET;ORAL	212436-003	Nov 1, 2019	7,456,168
Pfizer	IBRANCE	palbociclib	CAPSULE;ORAL	207103-001	Feb 3, 2015	6,936,612
Pfizer	IBRANCE	palbociclib	CAPSULE;ORAL	207103-003	Feb 3, 2015	7,456,168

EU/EMA Drug Approvals for IBRANCE

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Pfizer Europe MA EEIG	Ibrance	palbociclib	EMEA/H/C/003853Ibrance is indicated for the treatment of hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative locally advanced or metastatic breast cancer:in combination with an aromatase inhibitor;in combination with fulvestrant in women who have received prior endocrine therapy.In pre- or perimenopausal women, the endocrine therapy should be combined with a luteinizing hormone releasing hormone (LHRH) agonist.	Authorised	no	no	no	2016-11-09

International Patents for IBRANCE

When does loss-of-exclusivity occur for IBRANCE?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Argentina

Australia

Brazil

Canada

Chile

China

Colombia

Costa Rica

Croatia

Cyprus

Denmark

Dominican Republic

Ecuador

European Patent Office

Hong Kong

Hungary

Israel

Japan

Lithuania

Mexico

New Zealand

Peru

Poland

Portugal

Russian Federation

Saudi Arabia

Serbia

Singapore

Slovenia

South Africa

South Korea

Spain

Taiwan

Turkey

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering IBRANCE around the world.

Country	Patent Number	Title	Estimated Expiration
Argentina	094842
Australia	2014220354
Brazil	112015019508
Canada	2900322
China	105008357

Supplementary Protection Certificates for IBRANCE

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1470124	300863	Netherlands		PRODUCT NAME: PALBOCICLIB, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT; REGISTRATION NO/DATE: EU/1/16/1147 20161111
1470124	122017000014	Germany		PRODUCT NAME: PALBOCICLIB, OPTIONAL IN FORM EINES PHARMAZEUTISCH ANNEHMBAREN SALZES, ESTERS, AMIDES ODER EINES PRODRUGS HIERVON; REGISTRATION NO/DATE: EU/1/16/1147 20161109
1470124	PA2017013	Lithuania		PRODUCT NAME: PALBOCIKLIBAS, PASIRINKTINAI FARMACINIU POZIURIU PRIIMTINOS DRUSKOS, ESTERIO, AMIDO ARBA PROVAISTO PAVIDALU; REGISTRATION NO/DATE: EU/1/16/1147 20161109
1470124	C20170012 00212	Estonia		PRODUCT NAME: PALBOTSIKLIIB;REG NO/DATE: EU/1/16/1147 11.11.2016
1470124	CA 2017 00010	Denmark		PRODUCT NAME: PALBOCICLIB, EVENTUELT I FORM AF EN FARMACEUTISK ACCEPTABEL ESTER ELLER ET FARMACEUTISK ACCEPTABELT SALT, AMID ELLER PRODRUG; REG. NO/DATE: EU/1/16/1147/001-006 20161111

Last updated: June 22, 2026

IBRANCE (palbociclib) market dynamics and financial trajectory: exclusivity, generic and biosimilar risk, and revenue outlook

Executive summary. IBRANCE (palbociclib) remains a high-revenue oncology franchise in CDK4/6 inhibition with continued global uptake driven by label expansion and line-of-therapy use. The financial trajectory is shaped by: (1) patent and regulatory exclusivity timelines that delay first generic erosion and govern Paragraph IV risk, (2) competitive pressure from other CDK4/6 inhibitors (abemaciclib, ribociclib) with different safety, dosing, and trial evidence, (3) uptake patterns by tumor type and combination partner, and (4) distribution of prescribing volume across regions with differing reimbursement and patent enforceability. Core market dynamics now pivot on whether palbociclib can defend share versus ribociclib and abemaciclib as combination standards mature and as payers tighten cost-effectiveness scrutiny.

---

What drives IBRANCE palbociclib market dynamics in metastatic breast cancer today?

Featured snippet answer: IBRANCE market share is driven by (i) strong evidence in HR-positive, HER2-negative metastatic breast cancer, (ii) clinical positioning in first-line combination settings and subsequent lines, (iii) tolerability management versus competitors, and (iv) payer coverage and pricing pressure as CDK4/6 formularies mature.

Key demand engines

1. CDK4/6 combination standard of care
   • Real-world use heavily concentrates in HR+/HER2− metastatic breast cancer where CDK4/6 inhibitors are combined with endocrine therapy.
2. Line-of-therapy and sequencing
   • Demand depends on whether palbociclib is preferred as initial CDK4/6 or reserved after progression.
3. Payer controls
   • Patient access in major markets is increasingly governed by payer formularies, step edits, and budget impact models comparing class agents.

Competitive “substitution” factors vs ribociclib and abemaciclib

• Dosing convenience and adherence
  • Formulary preferences often track dosing schedules and supportive care burden.
• Adverse event management
  • Neutropenia and hematologic monitoring influence clinic workflow and cost-to-serve.
• Perceived efficacy by subgroup
  • Tumor biology and prior exposure patterns shape selection among the class.

Commercial sensitivity points

• Loss of exclusivity risk
  • Generic entry timing and patent strength determine the speed and depth of erosion.
• Label scope expansion
  • Additional indications can prolong effective exclusivity and broaden prescriber pools.
• International enforcement
  • Patent enforceability and Orange Book visibility (US) correlate with how quickly lower-cost competitors can launch in each country.

---

How has IBRANCE revenue trended and what financial levers matter next?

Featured snippet answer: The next phase of IBRANCE’s financial trajectory depends on class-level CDK4/6 pricing compression, share retention versus other inhibitors, and the effective timeline to US and ex-US generic entry driven by patent estates and exclusivity triggers.

Revenue trajectory framework

1. Base business durability
   • Palbociclib’s franchise strength is anchored by ongoing clinical use in HR+/HER2− disease.
2. Share defense
   • Revenue is exposed to substitution toward ribociclib and abemaciclib where they show practical or payer-favorable positioning.
3. Price erosion
   • Even without immediate generic launches, class competition increases pricing pressure through tendering and reimbursement edits.
4. Exclusivity step-down events
   • The largest step changes usually come when exclusivities and key patents expire or when early generic launches force settlements or launch-with-design-around strategies.

What to watch in earnings

• US prescriptions and realized net prices
  • Prescription volume indicates share retention; net price reflects payer pressure and contract dynamics.
• Channel mix
  • Hospital versus specialty pharmacy distribution alters realized margins.
• Geographic concentration
  • US-centric payers can react faster to generic risk; ex-US markets can experience delayed but sometimes abrupt erosion after local approvals.

---

When does IBRANCE lose exclusivity in the US and what does that imply for generic entry risk?

Featured snippet answer: Palbociclib’s US exclusivity and patent protections determine the earliest lawful generic or biosimilar-like (for small molecules: generic) entry; the practical risk window is governed by Orange Book-listed patents, their expiration dates, and whether Paragraph IV challenges have been filed or resolved.

US exclusivity and patent framework

• Regulatory exclusivity types
  • New Chemical Entity (NCE) exclusivity, patent term extensions (PTE), and pediatric exclusivity can affect effective market protection windows.
• Orange Book-driven launch timing
  • Generic manufacturers can file ANDAs with Paragraph IV certifications against listed patents, and launch timing is triggered by litigation outcomes.

How launch risk typically materializes for palbociclib

1. Paragraph IV filing
   • Signals probable challenger intent and reveals which Orange Book patents are targeted.
2. Litigation and settlement
   • Settlement can force delayed launch, carve out design-around products, or cap at certain strengths/forms.
3. Court decisions
   • Determinations on patent validity or infringement drive actual entry timing.
4. Commercial ramp
   • Generic erosion tends to accelerate after first year when multiple entrants and pricing promos arrive.

(Note: A complete, numeric US expiration timeline requires the specific Orange Book listing set and patent-by-patent expiration dates.)

---

What patents protect IBRANCE palbociclib in the US, and how strong is the patent estate?

Featured snippet answer: IBRANCE’s patent estate in the US is typically composed of composition-of-matter patents for palbociclib substance, formulation patents covering dosage forms and release properties, and additional patents for methods of use (combinations and dosing regimens). The estate strength is measured by the number of Orange Book listings per drug product, the remaining term on those patents, and whether key patents have survived challenges.

Patent layers to evaluate

1. Composition-of-matter
   • Usually controls earliest generic entry.
2. Formulation and manufacturing
   • Can slow “design around” by constraining tablet/capsule characteristics, excipients, crystallinity, and manufacturing parameters.
3. Method-of-use
   • Can restrict generic labeling and require carve-out strategies or eventual incremental launches.

How to assess strength for litigation and licensing

• Number of listed patents per product
• Remaining life by patent family
• Which patents have been asserted previously
• Whether settlements are “early entry” or “delayed entry”
• Whether competitors have adopted design-around formulations

(Note: Without the specific Orange Book patent list and expiration dates for palbociclib, a complete patent-by-patent strength scoring cannot be stated.)

---

Which companies are challenging IBRANCE with Paragraph IV ANDAs, and what outcomes affect launch timing?

Featured snippet answer: Paragraph IV ANDA challengers for palbociclib are identified through FDA ANDA records tied to Orange Book-listed patents and then validated by litigation dockets and settlement press releases. The commercial impact depends on whether the challenger secures a narrow launch carve-out or a full-label entry.

What matters most for market dynamics

• Number of challengers
  • Multiple filings increase the probability of earlier erosion or a settlement race.
• Patent targets
  • Challenging a late-expiring method-of-use patent can delay label entry even if composition-of-matter is earlier.
• Settlement terms
  • Most market-moving details are launch date, authorized strengths, and labeling restrictions.

(Note: A precise list of challengers and case outcomes requires the specific ANDA Paragraph IV docket and patent numbers.)

---

How does IBRANCE compare with ribociclib and abemaciclib in market positioning and payer behavior?

Featured snippet answer: CDK4/6 class selection typically reflects a mix of dosing convenience, toxicity profile management, and evidence perceptions in specific subgroups. Those factors drive differential formulary placement and prescription switching, shaping palbociclib revenue trajectory even before generic entry.

Key commercial differentiators

• Ribociclib
  • Often competes where prescribers prioritize observed efficacy patterns and combination protocols.
• Abemaciclib
  • Tends to attract preference where tolerability and dosing schedule align with prescriber workflows and where clinical evidence supports certain sequencing or disease features.

Class-level pricing dynamics

• Tendering and national formularies
  • Switch to a preferred agent can happen without generic entry.
• Real-world utilization
  • If one agent becomes a first-line standard, palbociclib demand can compress even while protected.

---

What formulations are protected for IBRANCE and how do dosage form patents affect generic design around?

Featured snippet answer: Palbociclib IP typically spans the active substance plus dosage forms and manufacturing constraints that generic manufacturers must replicate or circumvent to launch. Formulation protection can delay entry to specific strengths or require alternative manufacturing approaches.

Dosage form and strength considerations

• Strength-specific barriers
  • Some generic programs start with fewer strengths due to formulation constraints, leading to staggered erosion by SKU.
• Bioequivalence and excipient constraints
  • Formulation patents can force costly changes that are easier to litigate or settle on than to design around.

---

What FDA regulatory status and label scope support IBRANCE demand?

Featured snippet answer: IBRANCE demand tracks its FDA-approved indications and the durability of guideline-concordant use in HR+/HER2− metastatic breast cancer, with label expansions sustaining new patient starts and supporting combination adoption.

Regulatory signals that affect commercial uptake

• Label expansions
  • Expand the eligible patient pool and increase prescriber confidence.
• Safety labeling and dosing guidance
  • Influence real-world dosing continuity and persistence.
• Therapeutic monitoring requirements
  • Impact clinic adoption and cost-to-serve, shaping payer decisions.

(Note: A label-by-label indication table requires the exact FDA-approved indication list and dates.)

---

How do settlements and litigation affect IBRANCE financial exposure before generic launch?

Featured snippet answer: For patented small-molecule oncology drugs like IBRANCE, the main pre-launch financial exposure comes from settlement structure that can grant an earlier entry date, allow partial labeling carve-outs, or limit authorized strengths, all of which can trigger revenue step-down.

Settlement pathways that shift revenue

1. Delayed launch settlement
   • Protects revenue longer but may cost licensing or lead to multiple settlement rounds.
2. Design-around carve-outs
   • Allows limited generic entry earlier; erosion starts in the narrow segment first.
3. Multi-jurisdiction enforcement
   • Global settlements can drive ex-US entry timing and reduce overall franchise value.

---

What generic entry risks exist for IBRANCE in the US, and how fast does erosion usually occur?

Featured snippet answer: Generic entry risk is primarily driven by the expiration status of composition-of-matter and formulation patents plus the outcomes of Paragraph IV litigations. When entry occurs, palbociclib erosion typically accelerates over 6 to 24 months as additional entrants and pricing pressure increase.

Erosion mechanics

• First entrant pricing
  • Sets the initial discount curve versus branded net price.
• Follow-on generics
  • Increase competitive intensity and compress gross-to-net margins.
• Formulary and PA changes
  • Payers often broaden preferred generic coverage rapidly after launch.

(Note: Rate-of-erosion specifics depend on negotiated contract dynamics and number/timing of ANDA approvals.)

---

How large is IBRANCE revenue exposure by geography and which markets tend to erode first?

Featured snippet answer: Revenue exposure concentrates in high-prescribing oncology markets where patent enforcement and reimbursement frameworks support rapid price compression after generic entry. US typically acts as the earliest litigation and launch battleground; the speed elsewhere depends on local regulatory timelines and patent validity status.

Geographic risk categories

• US
  • Patent litigation and ANDA Paragraph IV timing determine first generic entry.
• EU and UK
  • National patent enforcement and local SPC/patent rules influence timing and outcomes.
• China and other ROW
  • Regulatory approval speed can outpace litigation, but enforceability determines actual pricing impact.

(Note: A numeric geographic breakdown requires revenue by region.)

---

What business strategy does the IBRANCE franchise support: lifecycle management, licensing, or new combinations?

Featured snippet answer: Lifecycle strategy for palbociclib typically emphasizes new combination regimens, new line-of-therapy positions, and practical dosing refinements that improve persistence and reduce discontinuation. Licensing and settlements can also manage the risk of earlier generic entry by buying time or securing non-exclusive arrangements.

Most relevant commercial levers

• Clinical evidence that expands guideline adoption
• Combination partner performance
• Real-world adherence and discontinuation mitigation
• Operational readiness for competitive intensity

---

Key Takeaways

• IBRANCE’s financial trajectory is shaped by CDK4/6 class competition and by exclusivity and patent enforceability that govern generic entry timing.
• Even without generic launch, market dynamics can shift through payer formulary decisions and evidence-based sequencing versus ribociclib and abemaciclib.
• The most material revenue downside step-change comes from generic erosion after US exclusivity and patent barriers fall, with settlement outcomes determining whether erosion begins with narrow carve-outs or full-label entry.
• Real-world dosing persistence and toxicity management affect share retention, often influencing net realized pricing through payer coverage behavior.

---

FAQs

1. How do Paragraph IV settlements for palbociclib typically structure launch dates and labeling carve-outs?
2. What is the comparative payer preference between palbociclib, ribociclib, and abemaciclib in HR+/HER2− metastatic breast cancer?
3. Do formulation patents for palbociclib prevent generic entry by strength, or do they delay full-scale launches?
4. How does label sequencing after progression on endocrine therapy influence palbociclib market uptake?
5. What ex-US patent enforcement patterns determine whether palbociclib erosion starts outside the US?

---

References

1. U.S. FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations (palbociclib/IBRANCE listings).
2. U.S. FDA. Drug Approval Package and labeling for IBRANCE (palbociclib).
3. FDA. ANDA and Paragraph IV certifications reporting (as available via FDA records).
4. CourtListener / PACER or comparable legal docket sources for palbociclib patent litigation (as available).

DrugChatter Q&A for IBRANCE

When will ibrance lose exclusivity in us?
Pfizer not covering ibrance 2025 only generic ibrance?
Pfizer ibrance manufactured where?
Pfizer ibrance tablet ep3302565b1 patent?
Is generic ibrance available?